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Summary
We showed previously that mouse mastocytoma P815 expresses several distinct antigens that
are recognized by cytolytic T lymphocytes (CTL) of syngeneic DBA/2 mice. Antigens P815A
and P815B are usually lost jointly and are targets for immune rejection responses in vivo. We
used a cosmid library and a CTL stimulation assay to obtain transfectants expressing tumor rejection
antigen P815A. From these transfectants we retrieved gene PlA which transferred the expression
of both P815A and B. This gene is unrelated to three previously isolated genes coding for turn -
antigens. It encodes a putative protein of 224 amino acids which contains two highly acidic
domains showing homology with similar regions of nuclear proteins. The PlA gene expressed
by tumor P815 is completely identical to the gene present in normal DBA/2 cells. Expression
of the gene was tested by Northern blots. Cells from liver, spleen, and a number of mast cell
lines were negative, but mast cell line L138.8A produced a high level of PlA message and was
lysed by CTL directed against antigens P815A and B. We conclude that major tumor rejection
antigens of P815 are encoded by a gene showing little or no expression in most normal cells
of adult mice.
M
ouse tumors express antigens that are targets of T cell
mediated rejection responses in the syngeneic animals.
The first evidence for the existence of these "tumor rejection
antigens" was obtained with experimental tumors induced
by chemical carcinogens such as methylcholanthrene (1, 2,
3). The antigens expressed by these tumors elicited immune
rejection responses and were different for every tumor. They
were named tumor-specific transplantation antigens (TSTA)t
(4). Later, similar antigens were observed on tumors induced
by ultraviolet radiation (5). Spontaneous tumors, on the other
hand, are usually nonimmunogenic and were therefore thought
to be devoid of tumor rejection antigens (6). However, im-
munogenic variants of spontaneous tumors were obtained by
mutagenesis and these variants were shown to induce an im-
mune protection against the original tumor (7). This indi-
cated that spontaneous mouse tumors express tumor rejec-
tion antigens which can constitute targets for syngeneic
rejection responses even though they are not immunogenic
on their own. Similar results have been obtained recently by
transfecting foreign genes into spontaneous tumors (8).
1 Abbreviations used in this paper: BrdU-bromodeoxyuridine; CTL, cytolytic
T lymphocytes; LB, Luria-Bertani; tk, thymidine kinase; TSTA, tumor-
specific transplantation antigens.
A number of tumor rejection antigens have been charac-
terized in vitro with cytolytic T lymphocytes (CTL) derived
from mice immunized with tumor cells and highly specific
CTL clones have been obtained (9, 10, 11, 12, 13). However,
the nature ofthese antigens has remained elusive because they
do not elicit any antibody response, and could therefore not
be isolated by immunoprecipitation. The same situation ap-
plies to other antigens recognized by CTL, such as minor
histocompatibility antigens, male-specific H-Y antigens (14),
and also turn - antigens, which are present on immunogenic
variants obtained by mutagen treatment of mouse tumor
cells (10).
We have recently cloned the genes coding for three tum -
antigens expressed by turn - variants of mouse tumor P815
(15, 16, 17). The cloning procedure involved gene transfec-
tion and the detection of antigen-expressing transfectants by
their ability to stimulate the appropriate CTL (18). The se-
quencing of the three genes revealed that they were com-
pletely unrelated and showed no homology with any gene
previously recorded in the data banks. For these three genes,
the allele borne by the turn - variants was found to differ
from the normal allele by a point mutation located in a coding
region (16, 17, 19). These mutations create new antigenic
peptides that are presented to the syngeneic CTL by a class
I molecule of the MHC.
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of mastocytoma P815, a tumor obtained in a DBA/2 mouse
treated with methylcholanthrene. These antigens are recog-
nized by CTL and are involved in the immune rejection re-
sponse occurring in vivo (20) . We report here the cloning
and analysis of a gene coding for a tumor rejection antigen
of P815 .
Materials and Methods
Cell Lines.
￿
Mastocytoma P815 was obtained in aDBA/2mouse
that hadbeen treated with methylcholanthrene. PI is a clonal line
isolated from apermanent cell line derived from the transplantable
P815-X2 subline (21) . The highly transfectable line P1.HTR.tk-
(referred to as P1.HTR) was derived from P1 after repeated cycles
of transfection and selection for thymidine kinase expression (tk')
followed by reverse selection with bromodeoxyuridine (BrdU) (22) .
PO.HTR cells were derived from the P1.HTR variant by im-
munoselection with CTL clones as described (12). L fibroblastic
cell line DAP-3 (H-2k) and transfected derivatives expressing
H-2Ld and H2-DI were a gift fromK. Ozato (National Institutes
of Health, Bethesda, MD) (23) . We obtained the transfectants ex-
pressing Kd by transfecting DAPL cells with plasmid p191 .1 (24) .
Theculturemedium wasDME (Gibco Laboratories, Grand Is-
land, NY) supplemented with 10% (v/v) FCS (Gibco Laborato-
ries) . P815 cells were cultured in tissue culture plasticware, and in-
cubated in water-saturated air containing 8% C02 at 37°C.
Medium for untransfected PO.HTR tk- was supplemented with
BrdU (100 Ftg/ml) Oanssen Chemica, Beerse, Belgium) until 4 d
before transfection to prevent appearance of tk' revertants. The
L138.8A mast cell line was a gift from L. Hultner (Institut far
Experimentelle Hamatologie, Manchen, FRG) (25, 26), and was
cultivated in RPMI medium supplemented with L-arginine (5.5
x 10_4 M), L-asparagine (2.4 x 10 -4 M), L-glutamine (1.5 x
10-3 M), 2-ME (5 x 10 -5 M), 10% FCS, and 10% I1,3-con-
taining culture supernatant ofWEHI-3B cells . Mast cell lineMC/9
was obtained from the American Type Culture Collection (Rock-
ville, MD) and cultivated in Iscove's modifiedDME supplemented
with 500 U/ml of rII-9 (a gift ofJ . Van Snick, Ludwig Institute
for Cancer Research, Brussels, Belgium) and with the same addi-
tives as in the medium used for L138.8A .
CTL Clones.
￿
The derivation fromDBA/2mice ofCTLclones
specific for P815 tumor antigens A, B, C, andD was described
previously (20) . We maintained CTL clones in long-term culture
by transferring every 3-4 d 5 x 104 CTL to 1 ml cultures con-
taining 5 x 106 irradiated (30 Gy) DBA/2 feeder spleen cells and
10 5 tk - P1.HTR cells as stimulators in 24-well tissue culture
plates. The culture medium wasDMEsupplemented with L-arginine
(5.5 x 10-4 M), t-asparagine (2.4 x 10' 4 M), L-glutamine (1.5
x 10-3 M), glucose (3.5 g/1), HEPES (10-Z M), 2-ME (5 x 10-5
M), and 10% FCS and HAT (10-4M hypoxanthine, 3.8 x 10 -'
M aminopterin, and 1.6 x 10 -5M 2-deoxythymidine) . In addi-
tion, cultures contained50% ofsupernatant from secondaryMLC
(27) as a source of growth factor. Forthe stimulation assays, CTL
cultures initiated4 d earlier were divided into two parts and sup-
plemented with an equal volume of fresh CTL culture medium
with 50%MLC supernatant . No fresh feeder cells or stimulator
cells were added . 2 d later, the CTL were harvested and added to
the microcultures of transfected cells .
DNA-mediated Gene Transfer and Selection of Tansfected Cells.
Plasmid and genomicDNA were prepared as described (18) . We
used a transfection procedure similar to the Corsaro and Pearson
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(28) modification of the method of Wigler et al . (29) . Cellular
DNA (60 Fg) and 3 ug of pHMR272 (30) were mixed in 940
P .1 of 1 mM Tris-Cl, pH 7.5, 0.1 mM EDTA ; 310 ul of CaC12
1Mwere then added. This solution was slowly addedunder con-
stant agitation to 1.25 ml of 50mM Hepes, 280mM NaCl and
1.5 mM NazHP04, adjusted to pH 7.1 withNaOH. Thecalcium
phosphate-DNA precipitates were allowed to form for 30-45 min
at room temperature. PO.HTR cells (5 x 106) were centrifuged
for 10 min at 400g. After removal of the supernatant, the pellets
were resuspended directly in the medium containing theDNA
precipitates . The mixture was incubated for 20 min at 37'C and
then added to a 80 cm' tissue culture flask containing 22.5 ml
DMEM supplemented with 10% FCS . After 24 h, the medium
was replaced . 48 h after transfection, the cells were collected and
counted. Selection of transfected cells in mass cultures was then
carried out in culture medium supplemented with hygromycin B
(350 ttg/ml) (Calbiochem-Behring Corp., San Diego, CA). For
each group two flasks were prepared with 8 x 106 cells in 40 ml
medium per flask . To estimate the number of independent trans-
fectants, 106 cells from each group were plated in 5 ml DMEM
with 10% FCS, 0.4% bactoagar (Difco Laboratories), and 300
pg/ml hygromycin B . Colonies were counted 12 d later. The av-
erage of two independent determinations was multiplied by 5 to
estimate the number of independent transfectants in the corre-
sponding group . A correction wasmade for the cloning efficiency
of P815 cells in agar, which was observed to be -0.3 .
Chromium Release Assayfor CTL Activity .
￿
Chromium release
assay was previously described (10) . Briefly, CTL were incubated
with 2,000 "Cr-labeled cells at various effector/target ratios in 96-
well conical microplates in a final volume of 200 /A1 . The chro-
mium released in the supernatant wasmeasured after 4 h of incu-
bation at 37°C .
. Screening ofTansfectants with CTL.
￿
8 d after the transfection,
the antibiotic-resistant transfectants were separated from the dead
cells by density centrifugation with Ficoll-Paque (Pharmacia Fine
Chemicals, Piscataway, NJ) and were maintained in nonselective
medium for 1 or 2 d . These cells were then plated in 96-well
microplates (round bottom) at 30 cells/well in 200 ILI of culture
medium. After 5 d, the wells contained -6 x 104 cellsand replica
plates were preparedby transferring 1/10 ofthewells to microplates
which were incubated at 30°C. 1 d later, the master plates were
centrifuged, the medium was removed and 750 CTIrP1 :5 (anti-
P815A) were added to each well together with 106 irradiated syn-
geneic feeder spleen cells in CTL culture medium containing 40
U/ml ofrecombinanthuman II-2 . Themedium also containedHAT
to kill the stimulator cells . 6 d later, the plates were examined visually
to identify the wellswherethe CTLhad proliferated. For the plates
where proliferating microcultures were observed, aliquots of 100
P,l of all the wells were transferred to another plate containing
"Cr-labeled P1.HTR target cells (2,000-4,000/well). Chromium
releasewas measured after4h(10) . The replica microcultures cor-
responding to the microcultures showinghigh CTL activity were
expanded andcloned by limiting dilution in DME with 10% FCS .
After 5 d, -200 clones were collected and screened with CTI-
P1:5 in a visual lysis assay.
Visual Lysis AssayforCTL Activity.
￿
Aliquots (-103/cells) from
individual clones were incubated either alone or together with 2
x 104 CTL in DME with 10% FCS on 96-well round-bottom
microplates (12) . Before use, the CTL were separated from dead
feeder and stimulator cells bydensity centrifugation on Ficoll-Paque.
1 d later, the plates were examined microscopically to compare the
number of surviving cells in the wells containing CTL to that in
the control wells .
Tumor P815 Gene Is Identical to the Normal Gene of Syngeneic DBA/2 MiceGenomic Libraries andCosmid Transfection .
￿
Total genomicDNA
of transfectant PlAT2 was partially digested with Sau3A1 and frac-
tionated by NaCl density gradient ultracentrifugation to enrich
for 35-50 kb DNA fragments (31) . These fragments were ligated
to cosmid arms of c2RB (32) that were obtained by cleavage with
Smal and treatment with calf intestinal phosphatase followed by
digestion with BamHl . The ligated DNA was packaged into X
phage components (Gigapack Gold ; Stratagene Cloning Systems,
LaJolla, CA) . The product was titrated on Escherichia coli ED8767
as described (31) . We obtained about 9 x 105 Ampil colonies per
microgram of DNA insert . To amplify the cosmid groups, pack-
aging mixtures representing 30,000 independent cosmids were
mixed with 2 ml of ED8767 bacteria in 10 MM MgC12, incubated
20 min at 37°C, diluted with 20 ml ofLuria-Bertani (LB) medium,
and incubated for 1 h . The suspension was titrated, then used to
inoculate 1 L ofLB medium in the presence ofampicillin (50 Irg/ml) .
When the bacterial concentration reached 2 x 108 cells/ml (OD6oo
= 0.8), a 10 ml aliquot was frozen and chloramphenicol (200 Rg/ml)
was added to the rest ofthe culture for overnight incubation . Total
cosmidDNA was isolatedby the alkaline lysis procedure and purified
on CsCl gradient . Groups of 5 x 106 PO.HTR cells were treated
with 60 jig ofDNA of each amplified cosmid group and 4 pg
of pHMR272 .
The genomic library of normal DBA/2 kidney cells was pre-
pared in X Zapll (Stratagene) . High mol wt DNA was digested
with EcoRI and fractionated by agarose gel electrophoresis . Frag-
ments from 6 to 8 kb were recovered from the gel and ligated to
EcoRl-digested A Zapll . The recombinant DNA was packaged in
A phage components and titrated onE. coli strains XL1-Blue and
PLK-A (Stratagene) . The screening of this library was performed
with thePIA probe a (Fig . 6) . The 8-kb insert of a positive clone
was transferred to plasmid vector pBluescript by in vivo excision
according to Stratagene's protocol.
Cosmid Recovery byDirectPackaging .
￿
High mol wtDNA ofthe
cosmid transfectants expressing P815A was directly packaged in
X phage components with Gigapack Gold extracts (Stratagene) .
The product was titrated on E. coli ED8767 with ampicillin selec-
tion . For transfection, these groups ofcosmids were amplified like
the cosmid library.
mRNA Analysis and cDNA Library .
￿
Total cellular RNA was
prepared by the guanidine-isothiocyanate procedure (33) . Poly-A'
mRNA was purified by chromatography on oligo-dTcellulose
column (Pharmacia Fine Chemicals) as described (33) .
For the Northern blot analysis, the RNA samples were frac-
tionated on 1% agarose gels containing 0.66M formaldehyde. Gels
were treated with 10x SSC (SSC:0.15M sodium chloride, 0.015
M sodium citrate [pH 7.0)) for 30 min before overnight blotting
on nitrocellulose membranes (BA85 ; Schleicher and Schuell, Inc.,
Keene, NH) . After 2 h baking at 80°C, the membrane was pre-
hybridized for 15 min at 60'C in a solution containing 10% dex-
tran sulfate (Pharmacia Fine Chemicals), 1% SDS, and 1M NaCI .
Hybridization was then performed by adding to the prehybridiza-
tion solution the denatured labeled specific probe together with
100 ug/ml denatured salmon sperm DNA . The human fl-actin
cDNA probe was kindlyprovided byA-M . Lebacq . The hybridiza-
tion was carried out overnight at 60°C . The blots were washed
twice at room temperature with 2x SSC and twice at 60°C with
2x SSC supplemented with 1% SDS . The P1 cDNA library was
prepared in A gt10 as described (34) . The DBA/2 mouse spleen
cDNA library was prepared inX gt10 using adaptors (cDNA cloning
system, Amersham kit ; Amersham Corp ., Arlington Heights, IL) .
DNA Sequencing and Homology Search.
￿
DNA sequence anal-
ysis was performed on clones generated by a variety of restriction
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digests and by specific priming with synthetic oligonucleotides .
All sequencing reactions were performed by the dideoxy chain-
termination method (United States Biochemicals Corp., Cleveland,
OH ; or Pharmacia Kit ; Pharmacia Fine Chemicals) . The computer
search for sequence homology was done with program FASTA,
with K-tuple parameters of3 and 6 (35) . Genbank database release
65 (October 1990) was used.
Amplification of the S' cDNA End by Polymerase Chain Reac-
tion. The amplification was performed as described (36) . The
primer for the synthesis of the cDNA corresponded to positions
320-303 . For the amplification, we used a 3' primer corresponding
to positions 286-266 and the 5' primers described by Frohman et
al . (36) . We obtained a band ofthe expected size (270 bases) which
hybridized with PIA probe a (Fig. 6) on a Southern blot . This
band was cloned in M13 tg130 and tg131 and was sequenced.
Results
We have shown previously that clonal cell line P1 derived
from tumor P815 expresses four distinct antigens recognized
by CTL of syngeneic DBA/2 mice immunized with P815
cells (20) . StableCTL clones, which showed strict specificity
for P815, were used to obtain antigen-loss variants of P815
by selecting in vitro tumor cells that were resistant to lysis.
Other antigen-loss variants that were also resistant to some
anti-P815 CTL clones were found in tumor cell populations
that had escaped immune rejection in vivo . Examples of
antigen-loss variants selected in vitro (isc) or in vivo (ist) are
shown in Fig. 1 . The analysis of these variants with a panel
of anti-P815 CTL clones revealed a total of four distinct an-
tigens, which were named P815A, B, C, and D. Antigens
P815A and B showed linkage : immune selection with anti-A
CTL repeatedly resulted in concurrent resistance to anti-B
CTL . However, one antigen-loss variant was resistant to anti-A
and not to anti-B CTL, suggesting that antigens A and B
might be distinct (Fig. 1) . The loss of antigens A and B on
several variants that had escaped immune rejection inDBA/2
mice, provided strong evidence for an essential role of these
antigens in the immune rejection response occurring in vivo
against P815 (20) .
Transfection with GenomicDNA .
￿
To clone the gene coding
for antigen P815A, we resorted to a gene transfection ap-
proach . The highly transfectable cell line P1.HTR, which
had been used successfully for the transfection of tum -
genes, was not a suitable DNA recipient, because it expressed
antigen A (22) . We therefore submitted P1.HTR to selec-
tion with anti-A CTL clone P1:5 and obtained a variant that
expressed neither antigen A nor B. An additional selection
with anti-C CTL clone P89:15 yielded clonePO.HTR which
had also lost C (Fig. 3) . This clone was used for all the trans-
fection experiments.
To screen the transfectants for expression of antigen A,
we relied on a test based on the ability of antigen-expressing
transfectants to stimulate anti-A CTL clone P1:5 (18) . In recon-
struction experiments, microwells were seeded with 750 CTL
and with a mixture of 1,500 P1.HTR cells (which express
A) and 44,000 PO.HTR cells (which do not) . A significant
proliferation of the CTL was observed visually after 5 d, and
the stimulation of the CTL was confirmed by testing theto
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Figure 1 .
￿
Antigens recognized by DBA/2 CTL on P815 clone PI and
on immunoselected variants. Antigen-loss variants P1.iscC- and P1.iscD -
were isolated byin vitro selectionwith anti-P815 CTL clones P89:15 (anti-C)
and P89:20 (anti-D), respectively. Antigen-loss variants P1.istA- and
P1.istA-B - were found in PI cell populations that had escaped tumor
rejection in vivo. These variants were resistant to anti-P815 CTL clone
P1:3 and CTL clone P35:10 which were defined as anti-A and anti-B, respec-
tively. The cytolytic activity was measured in a 4-h 51Cr release assay .
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Detection of transfectants expressing antigen P815A . (A) Reconstruction experiments with microcultures seeded with 750 anti-A CTL
(P1:5) and either no stimulating cells, 1,500 P1.HTR cells, 1,500 P1.HTR cells plus 44,000PO.HTR cells, or 44,000PI cells. After 6 d, the
lytic activity of the microcultures was tested against chromium-labeled P1.HTR cells. Each point represents the lyric activity of a single microculture.
(B) Detection of transfectants expressing antigen P815A in two groups ofPOI cells transfected with genomic DNA of Pl.HTR. For groups
5 and 14, 400 and 300 wells, respectively, were seeded with 30hygromycin-resistant transfected cells . After amplificationandduplication of these microcultures,
anti-A CTL clone P1:5 was added . 6 d later, the lytic activity of the microcultures was tested on P1.HTR. Each point represents the lytic activity
of a single microculture .
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lytic activity of aliquots ofthe microcultures against P1.HTR
(Fig . 2 A) . This indicated that identification of transfectants
expressing antigen A should be feasible by testing pools of
30 transfected cells .
Fifteen groups of 5 x 106 PO.HTR cells were transfected
with genomicDNA of P1.HTR and with selective plasmid
pHMR272, which confers hygromycin resistance. After se-
lection by hygromycin, the transfected populations were
amplified and distributed by pools of 30 cells into 100-400
microwells according to the number of independent hy-
gromycin-resistant transfectants obtained in each group. This
number, which was estimated by an agar colony test, varied
from 500 to 3,000 and our aim was to have each independent
transfectant represented in at least four microwells . The
microcultures were incubated until they contained approxi-
mately 6 x 104 cells. At this stage an aliquot was transferred
to a duplicate well and 750 anti-A CTL were added to each
microculture. 5 d later the proliferation oftheCTL was evalu-
ated visually . Three of the fifteen groups oftransfectants gave
a few positive microcultures. The lytic activity against P1.HTR
of all the microcultures of these groups was assessed by a
chromium release test and most microcultures where prolifer-
ation had been observed displayed a lytic activity well above
background (the results obtained with two positive groups
of transfected cells are shown in Fig . 2 B) . For each group,
the duplicate microcultures corresponding to several positive
wells were subcloned and more than 1% of the clones were
found to be lysed by the anti-A CTL. Thus, 3 independent
transfectants expressing antigen P815A were obtained from
a total of 33,000 hygromycin-resistant transfectants .
The transfectants were tested with CTL directed against
the P815 antigens . All three were lysed by the anti-A CTL
as effectively as P1.HTR . They were also lysedby anti-B CTL,
confirming the linkage between antigens A and B and sug-
gesting that these antigens were encoded by the same gene .
Results obtained with transfectant PlAT2 are shown in Fig. 3 .
Transfection with a Cosmid LibraryandRecovery ofthe Gene
Transferring the Expression of Antigens P815A and B .
￿
We
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Figure 3 . Sensitivity of P1.HTR, PO.HTR, genomic transfectant
PlAT2, and cosmid transfectant PlATC3 .1 to lysis by anti-A CTIrP1:5,
anti-BCTIrP35:10, anti-C CTI.P89:15, and anti-D CT1.P1.204:8 . Chro-
mium release was measured after 4 h .
showed previously that genes coding for tum - antigens
could be recovered directly from transfectants obtained with
a cosmid library (15) . This approach was therefore applied
to P815A . A library of 650,000 cosmids was prepared with
cosmid vector c2RB and DNA of genomic transfectant
PlAT2 . Twenty one groups of "30,000 cosmids were
amplified, the DNA of each group was transfected into
PO.HTR with plasmid pHMR272 and an average of 3,000
transfectants per group were tested for antigen expression .
The transfectants were screened for their ability to stimulate
anti-A CTL clone P1:5 as described for the genomic transfec-
tions . One group of cosmids repeatedly produced positive
transfectants at a frequency of about 1/5,000 drug-resistant
transfectants. Here again these transfectants expressed both
A and B. The sensitivity to anti-P815 CTL of cosmid trans-
fectant PlATC3.1 is shown in Fig. 3 .
The DNA of three independent cosmid transfectants was
isolated and packaged directly with A phage extracts (15) .
Cosmids were obtained for each transfectant . They were
pooled, amplified, and transfected into PO.HTR. The three
pools produced a high frequency of transfectants expressing
antigen A (Table 1) . By analysis with restriction enzymes,
we identified seven different cosmids in the pool of 32 cosmids
derived from transfectant PIA.TC3.1 . These cosmids were
transfected individually and four of them proved capable of
transferring the expression of antigens A and B . We selected
for further analysis cosmid ClA.3.1, which was only 16.7
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Figure 4 .
￿
Restriction map of cosmid ClA.3 .1. Restriction fragments,
cloned in vector pUC18 or obtained by electroelution were transfected
intoPO.HTR . 60 kg ofDNA were cotransfectedwith 4 ttg ofpHMR272
into 5 x 106 PO.HTR cells. After 2 d, dilutions of the cells were seeded
in agar plates containing hygromycin. 7 d later, the hygromycin resistant
(HmBr) colonies were transferred into microwells and tested individually
with anti-A CTL (P1:5) in a visual assay. The fragments shown in grey
were able to transfect the antigen . The 5.1-kb EcoRl fragment marked
"a" corresponds to the sequence of vector c2RB.
kb long, presumably because it had undergone partial dele-
tion during amplification .
The restriction map of ClA.3.1 is shown on Fig . 4 . All
the EcoRI restriction fragments were transfected, and only
the 7.4-kb EcoRI fragment produced transfectants that were
Table 1 .
￿
Transfer of the Expression of Antigen P815A by
Cosmids Obtained by Direct Packaging
" TheDNA of the transfectants indicated in the first row was packaged
in a X phage extract and used to infect E. coli ED8767. The number of
ampicillin-resistant bacterial colonies is indicated.
# TheDNA of the cosmids derived by direct packaging was cotransfected
in PO.HTR with pHMR272. Independent drug-resistant transfectants
were clonedby limiting dilution and were tested for lysis by anti-A CTL
P1 :5 in a visual assay .
CTL
anti-A anti-B anti-C anti-D
ell
Transfectant No . of cosmids No . of
obtained with obtained by direct transfectants expressing
the cosmid packaging of P815A/no, of
library 0.5 F,g of DNA' HmBr transfectantst
TC3 .1 32 87/192
TC3.2 32,000 49/384
TC3.3 44 25/72lysed with the anti-A CTL clone. Of the Pstl fragments, only
a 4.1-kb fragment, which was included in the 7.4-kb EcoRI
fragment, gave a positive result (Fig. 4) . Further digestion
of this fragment with Smal also produced a positive 2.3-kb
fragment . Finally, we found that a 900 bases SmaI/XbaI frag-
ment transferred efficiently the expression of antigen A . All
these fragments transferred the expression of antigen B also
(data not shown) .
Presentation ofAntigensP815A andP815B byLd.
￿
To iden-
tify the class I molecules responsible for presentation of an-
tigens A and B, cosmid ClA.3.1 was transferred into fibro-
blast lineDAP (H-2k), that had previously been transferred
Figure 5 .
￿
Northern blot analysis
oftheexpression ofgene PIA. Lanes
1-7 contained, respectively, 6, 2, 2,
2, 1, 5, and 2 lAg of poyA * RNA
ofthe cells indicated . Lane 1 was hy-
bridized with probe a (Fig. 6) of
gene PlA which crossreacted with
the mRNA of nucleolin (2 .6 kb)
and nucleolar protein N038/B23
(1.5 kb). Lanes 2-7 were hybridized
with probe b (Fig. 6) of gene PIA
and also with a i3-actin probe. Hy-
bridization with both probes were
performed either successively on the
same blot (lanes 2, 3, 4, and 7) or
simultaneously on two identical
blots (lanes 5 and 6) . Washing and
exposure conditions were the same
for the three probes.
with either Kd, Dd, or La . Both A and B were presented
to the appropriate CTL only by cells transferred with the
Ld gene (Table 2) .
StructureofGenePiA.
￿
The fragment of900 bases ofcosmid
ClA.3.1 that transferred the expression of antigen A was used
as a probe on a Northern blot prepared with poly-A+ RNA
ofP1.HTR. It revealed a band of 1.2 kb and two fainter bands
oflarger size (Fig. 5, lane 1) . Using the same probe to screen
a cDNA library prepared with poly-A+ RNA of P1, we
identified a cDNA clone. It had only a 1-kb insert, suggesting
that the 5' end was missing. Using oligonucleotides corre-
sponding to sequences of this cDNA, we obtained byPCR
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H-2-Restriction of Antigens P815A and P815B
Cosmid ClA.3 .1 containing the entire PlA gene was transfected in
DAP cells previously transfected with H-2d class I genes as indicated .
t Independent drug-resistant colonies were tested for lysis by anti-A or
anti-B CTL in a visual assay .
performed on P1.HTRcDNA a perfectly overlapping 5' end
sequence adding 200 bases (36) . This provided a plausible
1.2-kb sequence for the mRNA (Fig. 7) .
A 5 .7-kb region ofcosmid ClA.3.1, that included the SmaI-
Xbal transfecting fragment, was sequenced. The comparison
with the cDNA sequence delineated the exons indicated in
Fig. 6 and Fig. 7 . We concluded from these data that gene
PlA has a length ofapproximately 5 kb and comprises 3 exons .
An open reading frame coding for a putative protein of 224
amino acids starts in exon 1 and ends in exon 2 (Fig. 7) . The
fragment of 900 bases which transfers the expression of an-
tigens A and B contains only exon 1 . The promoter region
contains a CAAT box and an enhancer sequence which has
Pvu II
EcoR I
Pst I
Sph I
Sma I
￿
~'
Xba I
probe a
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been observed in the promoter of most MHC class I genes
(37, 38) .
A computer search revealed no significant similarity be-
tween gene PIA and sequences previously recorded in data
banks, with the exception ofa stretch of95 bases corresponding
to part of an acidic region encoded by exon 1 (positions 524
to 618) . This sequence is highly similar to sequences coding
for an acidic region in two nucleolar proteins, namely mouse
nucleolin (61 identical bases out of 95) and mouse nucleolar
protein N038/B23 (56 identical bases out of 95) (39, 40) .
To test whether these homologies provided the explanation
of the crosshybridizing bands found in the Northern blots,
we screened amouse spleencDNA library with the 900 bases
PlA fragment and we obtainedcDNA clones corresponding
closely to the sizes of the crosshybridizing bands . They were
partially sequenced and the 2.6-kb cDNA was found to cor-
respond exactly to the reported cDNA sequence of mouse
nucleolin whereas the 1.5-kb cDNA corresponded to the
mouse nucleolar protein N038/B23 .
The putative product of gene PlA has a Mr of25 kD. There
is a potential nuclear targeting signal (Fig . 7, residues 5-9)
(41) . A striking feature of protein PlA is the presence of a
large acidic domain located at positions 83-132, which in-
cludes the region of homology between PlA and the two
nucleolar proteins. This region contains a putative phosphory-
lation site (Ser 125) . Close to the C-terminus, there is a second
acidic domain, an uninterrupted stretch of 14 glutamate
residues . A similar C-terminal region was found in a murine
homeodomain protein, which was shown to have a nuclear
localization (42) .
The PIA Sequence Is Identical in Tumor P815 and in Kidney
Cells.
￿
A A phage library was prepared with the DNA of
4 14 4
probe b OL--------------------jo_--
ORF
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Figure 6.
￿
Structure of gene PIAand restriction sites . Thebox represents the part that was sequenced with the exons in black and the open reading
frame (ORF) of exons 1 and 2 . The 0.9-kb SmaI/XbaI fragment, which is able to transfer the expression of the antigen is delineated as probe a .
Probeb is an incompletecDNA of0.6 kb . The region preceding the SphI site at -0 .8 is rearranged in cosmid CIA.M . The gene was retrieved from
anotherlibrary where it was not rearranged as seen by comparison with genomic Southern blots. The restriction map indicated here is the genomicmap.
Recipient cell`
No . of clones lysed
CTL/no . of HmB`
CTL anti-A
by the
clonest
CTL anti-B
DAP (H-2k) 0/208 0/194
DAP+ Kd 0/165 0/162
DAP+Dd 0/157 0/129
DAP+Ld 25/33 15/20ACCACAGGAGAATGAAAAGAACCCGGGACTCCCAAAGACGCTAGATGTGTGAAGATCCTGATCACT CATTGGGTGTC
￿
-115
TGAGTTCTGCGATATTCATCCCTCAG CCAAT GAGCTTACTGTTCTCGTGGGGGGTTTGTGAGCCTTGGGTAGGAAGT -38
TTTGCAAGTTCCGCCTACAGCTCTAGCTTGTGAATTT
￿
OGTACCCTTTCACGTAAAAAAGTAGTCCAGAGTTT 34
ACTACACCCTCCCTCCCCCCTCCCACCTCGTGCTGTGCTGAGTTTAGAAGTCTTCCTTATAGAAGTCTTCCGTATAGAA 113
CTCTTCCGGAGGAAGGAGGGAGGACCCCCCCCCTTTGCTCTCCCAGCATGCATTGTGTCAACGCCATTGCACTGAGCTG 192
GTCGAAGAAGTAAGCCGCTAGCTTGCGACTCTACTCTTATCTTAACTTAGCTCGGCTTCCTGCTGGTACCCTTTGTGCC 271
ATG TCT GAT AAC AAG AAA CCA GAC AAA GCC CAC AGT GGC TCA GGT GGT GAC GGT GAT GGG 331
Met Ser Asp Asn Lys Lys Pro Asp Lys Ala His Ser Gly Ser Gly Gly Asp Gly Asp Gly
AAT AGG TGC AAT TTA TTG CAC CGG TAC TCC CTG GAA GAA ATT CTG CCT TAT CTA GGG TGG 391
Asn Arg Cys Asn Leu Leu His Arg Tyr Ser Leu Glu Glu Ile Leu Pro Tyr Leu Gly Trp
CTG GTC TTC GCT GTT GTC ACA ACA AGT TTT CTG GCG CTC CAG ATG TTC ATA GAC GCC CTT
￿
451
Leu Val Phe Ala Val Val Thr Thr Ser Phe Leu Ala Leu Gln Met Phe Ile Asp Ala Leu
TAT GAG GAG CAG TAT GAA AGG GAT GTG GCC TGG ATA GCC AGG CAA AGC AAG CGC ATG TCC
￿
511
Tyr Glu Glu Gln Tyr Glu Arg Asp Val Ala Trp Ile Ala Arg Gln Ser Lys Arg Met Ser
TCT GTC GAT GAG GAT GAA GAC GAT GAG GAT GAT GAG GAT GAC TAC TAC GAC GAC GAG GAC 571
Ser Val Asp Glu Asp Glu Asp Asp Glu Asp Asp Glu Asp Asp Tyr Tyr Asp Asp Glu Asp
￿
Figure 7 .
￿
Sequence ofthe three exons
GAC GAC GAC GAT GCC TTC TAT GAT GAT GAG GAT GAT GAG GAA GAA GAA TTG GAG AAC CTG
￿
631
￿
and of the 5' region of gene PlA and
Asp Asp Asp Asp Ala Phe Tyr Asp Asp Glu Asp Asp Glu Glu Glu Glu Leu Glu Asn Leu
￿
sequence of the protein encoded by the
ATG GAT GAT GAA TCA GAA GAT GAG GCC GAA GAA GAG ATG AGC GTG CAA ATG GGT GCC GGA
￿
691
￿
longest open reading frame . The num-
Met Asp Asp Glu Ser Glu Asp Glu Ala Glu Glu Glu Met Ser Val Glu Met Gly Ala Gly
￿
bering corresponds to the scale of Fig.
6 . The nucleotide indicated as the first
in exon 1 corresponds to the 5'cDNA
end obtained by thePCR. Boxes show
AGG AAG AAT GAA GTG AAG TGT AGG ATG ATT TAT TTC TIC CAC GAC CCT AAT TTC CTG GTG
￿
3244
￿
an enhancer sequence reported to be Pro Asn Phe Leu val
￿
present in the promoter ofmostMHC
TCT ATA CCA GTG AAC CCT AAG GAA CAA ATG GAG TGT AGG TGT GAA AAT GCT GAT GAA GAG
￿
3304
￿
class I genes (37, 38), aCAATbox, and
Ser Ile Pro Val Asn Pro Lys Glu Gln Met Glu Cys Arg Cys Glu Asn Ala Asp Glu Glu
￿
a consensus polyadenylation site. The
GGA AAC
￿
3364
￿
start of the poly(A) tail is indicated by
Val Ala Met Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Met Gly Asn
￿
an arrow. In the amino acid sequence,
a putativenuclear targeting signal is un-
derlined, as well as two regions rich in
acidic residues . The sequence between
position -0.7 to 5 (Fig. 6) is available
from EMBL/GenBank under accession
number M36386 . ThecDNA sequence
is also recorded in EMBL/GenBank
under accession number M36387 .
GCT GAG GAA ATG GGT GCT GGC GCT AAC TGT GCC T .. .
￿
O . ..GT GTT
Ala Glu Glu Met Gly Ala Gly Ala Asn Cys Ala
￿
Cys Val
Arg Lys Asn Glu Val Lys Cys Arg Met Ile Tyr Phe Phe
GTT GCA ATG GAA GAG GAA GAA GAA GAA GAG GAG GAG GAG
CCG GAT GGC TTC TCA CCT TAG GCATGCAG.. .
Pro Asp Gly Phe Ser Pro Amb
T AAAAATAAAA GTTTGACTTGCATAC ACTACAGTTGTTT
His Asp
CCT
Pro
GAG GAA GAG
GGC CAT CAT TTA 3184
Gly His His Leu
GAA ATG
O ...TTGCAAAGCCCAGAAGAAAGAAATGGACAGCGGAAG
AAGTGGTTGTTTTTTTTTCCCCTTCATTAATTTTCTAGTTTTTAGTAATCCAGAAAATTTGATTTTGTTCTAAAGTTCA
TTATGCAAAGATGTCACCAACAGACTTCTGACTGCATGGTGAACTTTCATATGATACATAGGATTACACTTGTACCTGT
DBA/2 kidney cells and a clone hybridizing with a PlA probe
was identified . From this clone, which contained exon 1 and
2 of gene PlA, the sequence corresponding to positions -0.7
to 3.8 of Fig . 6 was obtained . The sequence from 3.8 to 4.5
was obtained by PCR implication of kidney DNA . We did
not find a single difference between these sequences and that
of the gene carried by the P815 tumor cells. Moreover, when
the gene isolated from kidney cells was transfected into
PO.HTR, it transferred the expression of antigens A and B
as efficiently as the gene isolated from P815 (Fig. 8) . We con-
clude that the expression of these antigens by tumor P815
does not result from a mutation affecting the protein pro-
duced by gene PlA .
No evidence was found that a rearrangement had occurred
in the near vicinity of the gene carried by P815 cells. Southern
blot analysis with a probe containing exon 1 revealed an EcoRI
band and a PstI band of the same size, 8 kb and 5 kb, respec-
tively, in P815 cells and in kidney cells . An exon 3 probe re-
vealed anEcoRI band of2.3 kb in both cells (data not shown) .
Expression ofGenePIA.
￿
The 1.2-kb mRNA ofgene PlA
was not observed on Northern blots prepared with RNA
4323
4402
4481
4520
of liver or spleen cells of DBA/2 mice (Fig . 5), suggesting
that most normal cells do not express gene PlA .
Because P815 was originally described as a mastocytoma,
we also tested a number of mast cell lines for expression of
the gene . Mast cell line MC/9 (43) and short term cultures
of mast cells isolated from mouse bone marrow were nega-
tive on Northern blots (data not shown) . In contrast, a strong
signal was obtained with L138.8A (Fig. 5), a mast cell line
derived fromBALB/c bone marrow by culture in conditioned
medium containing IIr3 (25) . We took advantage of the fact
that BALB/c and DBA/2 mice share the H-2d haplotype to
test the sensitivity of cultured L138.8A to lysis by anti-P815
CTL clones . A high level of lysis was observed with anti-A
and anti-B CTL, but not with anti-C and anti-DCTL (Fig. 9) .
Mouse tumor cell lines of other histology were also tested
for expression o£ gene PlA : Northern blots of teratocarci-
noma cell line PCC4 (44) and of leukemias LEC (7) and
WEHI-3B were all negative.
Discussion
We have isolated a gene coding for a tumor rejection an-
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Figure 8.
￿
Transfections with gene PIA isolated from tumor P815 or
from normal cells . Restriction fragments containing the two first exons
ofgene PlA isolated from P815 or from normal DBA/2 kidney cells and
cloned in pUC18 or in pBluescript respectively were transfected into
PO.HTR . 60 lAg ofDNA were cotransfected with 4 ug of pHMR272
into 5 x 106 PO.HTR cells. After 6 d of selection in hygromycin, the
population of HmB1 transfectants was chromium-labeled and tested with
CTI,PI :5 (anti-A) and CTIrP35:10 (anti-B) in a 4-h chromium release
assay. Lysis of PO.HTR is shown as control .
tigen by an approach involving the transfection of a cosmid
library. This approach had been used previously to clone three
genes coding for turn - antigens (15, 16, 17, 18) and our
results provide additional evidence for its wide applicability.
It is nevertheless worth mentioning that a library of 1,400,000
cosmids derived from P815 cells failed to provide any trans-
fectants expressing antigen P815A, even though a total of
100,000 independent transfectants were tested . We then de-
rived another library from a genomic transfectant expressing
antigen P815A in the expectation that theDNA surrounding
the transfected gene might be different and perhaps less in-
hibitory to cosmid integration and multiplication . We were
successful, but it would be premature to conclude that the
use of transfectant DNA to build the cosmid library was a
decisive factor.
No significant similarity with the sequence of PlA was
found in gene data banks except for the sequences of two
genes coding for nucleolar proteins that share an acidic do-
main (39, 40, 45) . Proteins of the myc family of oncogenes
also belong to this class of nuclear proteins (40, 46), but no
significant homology was found between the sequences of
myc and PlA .
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Figure 9.
￿
Sensitivity of L138.8A mast cell line to lysis by anti-A CTL
P1:5, anti-B CTIrP35 :10, anti-C CTI P89:15, and anti-D CTI,P1.204:8.
Lysis ofPLHTR is shown as control. Chromium release was measured
after 4 h .
Both anti-A and anti-B CTL recognize a product of gene
PlA in association with Ld . To establish the exact relation
between the epitopes recognized by these two CTL, it will
be necessary to identify the relevant antigenic peptides . P815A
and B may correspond to two different peptides encoded by
PlA . Alternatively, the two CTL may recognize the same
peptide, but with different affinities, so that a decrease in the
amount of peptide bound to Ld may affect recognition by
anti-A CTL more deeply than that by anti-B.
Unlike the three genes coding for turn - antigens, the an-
tigenicity of gene PlA does not result from a point mutation
that modifies its protein product. There is no sequence differ-
ence between the gene expressed in tumor P815 and that
present in normal cells ofDBA/2 mice. Moreover, transfec-
tion of the gene isolated from normal DBA/2 kidney cells
confers sensitivity to anti-A and anti-B CTL . We conclude
that tumor rejection antigens P815A and B result from the
expression by tumor P815 ofa gene that is silent or expressed
at a very low level in most if not all normal cells of adult
mice. This suggests a correlation between expression ofgene
PlA and antigenicity, in contradiction with an hypothesis
that we considered (47) .
To the extent that tumor rejection antigens would be gener-
ated by point mutations like the turn - antigens, one would
expect that these antigens would be strictly specific for in-
dividual tumors . On the other hand, the identity of gene
PlA carried by tumor P815 with the gene carried by normal
cells suggests that some tumor rejection antigens maybe shared
by independent tumors ofthe same histology. Antigens P815A
andB are shared by P815 and by mast cell line L138.8A, which
incidentally is tumorigenic inDBA/2 mice . This differs from
the conclusions drawn from the study ofmethylcholanthrene-
induced sarcomas which express a large variety of tumor re-
jection antigens (4) . It is difficult at the present time to com-
pare our results with those obtained for antigens of sarcoma
CTL
anti-A anti-13 anti-C anti-D
CTL
anti-P815A
CTL
anti-P81513
TARGETS
so
60
P0 .HTR J
40-
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40
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0
kidney cellsMethA because these antigens were isolated on the basis of
their ability to stimulate immune responses in vivo and not
as targets of CTL (48, 49) . Clearly more genes need to be
analyzed to decide whether the situation observed with PlA
is the rule or the exception .
Mice that reject P815 cells do not present obvious health
impairment . How can antigens, that are encoded by normal
genes, elicit animmune rejection response against the tumor
without severe autoimmune consequences? A first explana-
tion may be provided by the long-standing notion of "on-
cofetal" antigens, implying that tumors reexpress fetal an-
tigens which have disappeared from all normal cells before
the establishment of immunological tolerance . Hence the ab-
sence of tolerance for these antigens and the absence of au-
toimmune consequences of the response, since no normal cell
of the adult animal would express these antigens. An alter-
native possibility is that gene PlA is expressed by mast cell
precursors located in the bone marrow during a brief stage
of their differentiation . These cells would not by themselves
induce an immune response either because of tolerance or
because oftheir small number and dispersion. The antitumoral
response might eliminate some of these precursor cells, but
after the rejection of the tumor, the active effector T cells
would disappear and mast cell differentiation could resume
without damage. To clarify these issues, we intend to carry
out a systematic analysis of the expression ofPlA messenger
RNA in adult and fetal tissues.
We consider that the product of gene PlA represents a
major tumor rejection antigen of tumor P815 for the fol-
lowing reasons . First, more than 10 independent occurrences
of P815 tumor-escape after nearly complete rejection produced
P815 cells that had lost the expression of antigens PlA-B.
Moreover, when these antigen-loss variants were injected into
mice, we never observed the partial rejection phase (20) .
Second, inmany mice thatmount an immune response against
P815, the major part of theCTL activity is directed against
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antigens PlAB . However, it is worth pointing out that there
is as yet no evidence that antigens P815A and B can elicit
a T cell response on their own . P815 expresses at least two
other antigens recognized by CTL . One cannot exclude that
a response against these antigens creates conditions that
strongly facilitate the response against A and B. This would
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